ArticlePediatric pulmonology2025
Efficacy of Noninvasive Neurally Adjusted Ventilatory Assist (NIV-NAVA) for Neonates With Transient Tachypnea of the Newborn: A Retrospective Analysis.
Article in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Triggering modalities to synchronise non-invasive respiratory support in preterm infants: a systematic review and meta-analysis.BMJ paediatrics open · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNoninvasive neurally adjusted ventilatory assist (NIV-NAVA) provides synchronized respiratory support based on diaphragmatic electrical activity and has shown efficacy in preterm neonates. However, its efficacy in late preterm and term neonates with transient tachypnea of the newborn (TTN) remains unclear.
methodsWe retrospectively analyzed 183 neonates (≥ 34 weeks' gestation) with TTN between 2016 and 2024 who received initial respiratory support with either NIV-NAVA (n = 68) or sigh positive airway pressure (SiPAP, n = 115). After propensity score matching (PSM), we compared primary outcomes of intubation and treatment failure, the latter defined as a device switch within 6 h. Secondary outcomes included the duration of oxygen therapy.
resultsAfter PSM, 84 neonates (42 per group) were included. The intubation rates did not differ significantly between the SiPAP and NIV-NAVA groups (21.4% vs. 7.1%; p = 0.116). However, treatment failure was significantly lower in the NIV-NAVA group (31.0% vs. 7.1%; p = 0.011) and a shorter duration of oxygen therapy (median, 18 vs. 6 h; p = 0.031). No significant adverse events were observed in either group.
conclusionNIV-NAVA appears to be an effective alternative to SiPAP for managing TTN in late preterm and term neonates. It demonstrated a comparable intubation rate while offering the significant benefits of reducing treatment failure and the duration of oxygen therapy. Further large-scale, prospective studies are warranted to confirm these important findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.